Trials / Completed
CompletedNCT00650533
Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg
Single-Dose Food In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Mylan Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to investigate the bioequivalence of Mylan's glimepiride 1 mg tablets to Aventis Amaryl® 1 mg tablets following a single, oral 1 mg (1 x 1 mg) dose administered under fed conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glimepiride Tablets 1 mg | 1mg, single dose fed |
| DRUG | Amaryl® Tablets 1 mg | 1mg, single dose fed |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2004-12-01
- Completion
- 2004-12-01
- First posted
- 2008-04-01
- Last updated
- 2024-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00650533. Inclusion in this directory is not an endorsement.